Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
39
CABA Quote, Financials, Valuation and Earnings
Last price:
$2.20
Seasonality move
:
-11.03%
Day range:
$2.12 - $2.20
52-week range:
$0.99 - $3.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.52x
Volume:
2.8M
Avg. volume:
2.3M
1-year change:
-6.41%
Market cap:
$211.3M
Revenue:
--
EPS (TTM):
-$2.53
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CABA
Cabaletta Bio, Inc.
|
-- | -$0.46 | -- | -27.29% | $14.13 |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -$0.15 | -- | -22.97% | $22.00 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
OCGN
Ocugen, Inc.
|
$440K | -$0.06 | 12.57% | -20.55% | $9.00 |
|
RNAC
Cartesian Therapeutics, Inc.
|
$177.6K | -$0.63 | -90.89% | -15.55% | $35.29 |
|
VSTM
Verastem, Inc.
|
$5.8M | -$0.61 | -88.84% | -63.78% | $16.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CABA
Cabaletta Bio, Inc.
|
$2.20 | $14.13 | $211.3M | -- | $0.00 | 0% | -- |
|
AVXL
Anavex Life Sciences Corp.
|
$3.72 | $22.00 | $331.9M | -- | $0.00 | 0% | -- |
|
CRMD
CorMedix, Inc.
|
$12.19 | $19.00 | $960.4M | 5.94x | $0.00 | 0% | 4.10x |
|
OCGN
Ocugen, Inc.
|
$1.44 | $9.00 | $449.7M | -- | $0.00 | 0% | 79.04x |
|
RNAC
Cartesian Therapeutics, Inc.
|
$6.76 | $35.29 | $175.8M | -- | $0.00 | 0% | 75.41x |
|
VSTM
Verastem, Inc.
|
$7.87 | $16.00 | $592.8M | -- | $0.00 | 0% | 36.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CABA
Cabaletta Bio, Inc.
|
15.6% | 6.169 | 11.44% | 3.50x |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -0.800 | -- | 11.47x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
OCGN
Ocugen, Inc.
|
90.32% | 2.409 | 6.48% | 1.60x |
|
RNAC
Cartesian Therapeutics, Inc.
|
-54.23% | 1.511 | 4.74% | 10.44x |
|
VSTM
Verastem, Inc.
|
121% | -1.113 | 15.18% | 2.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CABA
Cabaletta Bio, Inc.
|
-$345K | -$46.6M | -90.44% | -103.46% | -- | -$34.6M |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -$10.8M | -44.87% | -44.87% | -- | -$8.6M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
OCGN
Ocugen, Inc.
|
$802K | -$17.6M | -139.38% | -345.08% | -1005.99% | -$13M |
|
RNAC
Cartesian Therapeutics, Inc.
|
$452K | -$21.1M | -- | -- | -4660.62% | -$20.1M |
|
VSTM
Verastem, Inc.
|
$9.3M | -$40.7M | -369.69% | -1773.4% | -362.17% | -$44.5M |
Cabaletta Bio, Inc. vs. Competitors
-
Which has Higher Returns CABA or AVXL?
Anavex Life Sciences Corp. has a net margin of -- compared to Cabaletta Bio, Inc.'s net margin of --. Cabaletta Bio, Inc.'s return on equity of -103.46% beat Anavex Life Sciences Corp.'s return on equity of -44.87%.
Company Gross Margin Earnings Per Share Invested Capital CABACabaletta Bio, Inc.-- -$0.44 $165.2M AVXLAnavex Life Sciences Corp.-- -$0.11 $94.9M -
What do Analysts Say About CABA or AVXL?
Cabaletta Bio, Inc. has a consensus price target of $14.13, signalling upside risk potential of 547.94%. On the other hand Anavex Life Sciences Corp. has an analysts' consensus of $22.00 which suggests that it could grow by 489.81%. Given that Cabaletta Bio, Inc. has higher upside potential than Anavex Life Sciences Corp., analysts believe Cabaletta Bio, Inc. is more attractive than Anavex Life Sciences Corp..
Company Buy Ratings Hold Ratings Sell Ratings CABACabaletta Bio, Inc.7 2 0 AVXLAnavex Life Sciences Corp.2 1 0 -
Is CABA or AVXL More Risky?
Cabaletta Bio, Inc. has a beta of 3.171, which suggesting that the stock is 217.108% more volatile than S&P 500. In comparison Anavex Life Sciences Corp. has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.531%.
-
Which is a Better Dividend Stock CABA or AVXL?
Cabaletta Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anavex Life Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cabaletta Bio, Inc. pays -- of its earnings as a dividend. Anavex Life Sciences Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CABA or AVXL?
Cabaletta Bio, Inc. quarterly revenues are --, which are smaller than Anavex Life Sciences Corp. quarterly revenues of --. Cabaletta Bio, Inc.'s net income of -$44.9M is lower than Anavex Life Sciences Corp.'s net income of -$9.8M. Notably, Cabaletta Bio, Inc.'s price-to-earnings ratio is -- while Anavex Life Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cabaletta Bio, Inc. is -- versus -- for Anavex Life Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CABACabaletta Bio, Inc.-- -- -- -$44.9M AVXLAnavex Life Sciences Corp.-- -- -- -$9.8M
-
Which has Higher Returns CABA or CRMD?
CorMedix, Inc. has a net margin of -- compared to Cabaletta Bio, Inc.'s net margin of 49.9%. Cabaletta Bio, Inc.'s return on equity of -103.46% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital CABACabaletta Bio, Inc.-- -$0.44 $165.2M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About CABA or CRMD?
Cabaletta Bio, Inc. has a consensus price target of $14.13, signalling upside risk potential of 547.94%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 55.87%. Given that Cabaletta Bio, Inc. has higher upside potential than CorMedix, Inc., analysts believe Cabaletta Bio, Inc. is more attractive than CorMedix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CABACabaletta Bio, Inc.7 2 0 CRMDCorMedix, Inc.4 0 0 -
Is CABA or CRMD More Risky?
Cabaletta Bio, Inc. has a beta of 3.171, which suggesting that the stock is 217.108% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock CABA or CRMD?
Cabaletta Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cabaletta Bio, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CABA or CRMD?
Cabaletta Bio, Inc. quarterly revenues are --, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Cabaletta Bio, Inc.'s net income of -$44.9M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Cabaletta Bio, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cabaletta Bio, Inc. is -- versus 4.10x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CABACabaletta Bio, Inc.-- -- -- -$44.9M CRMDCorMedix, Inc.4.10x 5.94x $104.3M $108.6M
-
Which has Higher Returns CABA or OCGN?
Ocugen, Inc. has a net margin of -- compared to Cabaletta Bio, Inc.'s net margin of -1144.46%. Cabaletta Bio, Inc.'s return on equity of -103.46% beat Ocugen, Inc.'s return on equity of -345.08%.
Company Gross Margin Earnings Per Share Invested Capital CABACabaletta Bio, Inc.-- -$0.44 $165.2M OCGNOcugen, Inc.45.78% -$0.07 $36.5M -
What do Analysts Say About CABA or OCGN?
Cabaletta Bio, Inc. has a consensus price target of $14.13, signalling upside risk potential of 547.94%. On the other hand Ocugen, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 525%. Given that Cabaletta Bio, Inc. has higher upside potential than Ocugen, Inc., analysts believe Cabaletta Bio, Inc. is more attractive than Ocugen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CABACabaletta Bio, Inc.7 2 0 OCGNOcugen, Inc.3 0 0 -
Is CABA or OCGN More Risky?
Cabaletta Bio, Inc. has a beta of 3.171, which suggesting that the stock is 217.108% more volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 4.540, suggesting its more volatile than the S&P 500 by 354.007%.
-
Which is a Better Dividend Stock CABA or OCGN?
Cabaletta Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cabaletta Bio, Inc. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CABA or OCGN?
Cabaletta Bio, Inc. quarterly revenues are --, which are smaller than Ocugen, Inc. quarterly revenues of $1.8M. Cabaletta Bio, Inc.'s net income of -$44.9M is lower than Ocugen, Inc.'s net income of -$20.1M. Notably, Cabaletta Bio, Inc.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cabaletta Bio, Inc. is -- versus 79.04x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CABACabaletta Bio, Inc.-- -- -- -$44.9M OCGNOcugen, Inc.79.04x -- $1.8M -$20.1M
-
Which has Higher Returns CABA or RNAC?
Cartesian Therapeutics, Inc. has a net margin of -- compared to Cabaletta Bio, Inc.'s net margin of -7942.92%. Cabaletta Bio, Inc.'s return on equity of -103.46% beat Cartesian Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CABACabaletta Bio, Inc.-- -$0.44 $165.2M RNACCartesian Therapeutics, Inc.-97.65% -$1.38 -$23.2M -
What do Analysts Say About CABA or RNAC?
Cabaletta Bio, Inc. has a consensus price target of $14.13, signalling upside risk potential of 547.94%. On the other hand Cartesian Therapeutics, Inc. has an analysts' consensus of $35.29 which suggests that it could grow by 421.98%. Given that Cabaletta Bio, Inc. has higher upside potential than Cartesian Therapeutics, Inc., analysts believe Cabaletta Bio, Inc. is more attractive than Cartesian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CABACabaletta Bio, Inc.7 2 0 RNACCartesian Therapeutics, Inc.6 2 0 -
Is CABA or RNAC More Risky?
Cabaletta Bio, Inc. has a beta of 3.171, which suggesting that the stock is 217.108% more volatile than S&P 500. In comparison Cartesian Therapeutics, Inc. has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.39%.
-
Which is a Better Dividend Stock CABA or RNAC?
Cabaletta Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cartesian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cabaletta Bio, Inc. pays -- of its earnings as a dividend. Cartesian Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CABA or RNAC?
Cabaletta Bio, Inc. quarterly revenues are --, which are smaller than Cartesian Therapeutics, Inc. quarterly revenues of $452K. Cabaletta Bio, Inc.'s net income of -$44.9M is lower than Cartesian Therapeutics, Inc.'s net income of -$35.9M. Notably, Cabaletta Bio, Inc.'s price-to-earnings ratio is -- while Cartesian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cabaletta Bio, Inc. is -- versus 75.41x for Cartesian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CABACabaletta Bio, Inc.-- -- -- -$44.9M RNACCartesian Therapeutics, Inc.75.41x -- $452K -$35.9M
-
Which has Higher Returns CABA or VSTM?
Verastem, Inc. has a net margin of -- compared to Cabaletta Bio, Inc.'s net margin of -876.34%. Cabaletta Bio, Inc.'s return on equity of -103.46% beat Verastem, Inc.'s return on equity of -1773.4%.
Company Gross Margin Earnings Per Share Invested Capital CABACabaletta Bio, Inc.-- -$0.44 $165.2M VSTMVerastem, Inc.82.57% -$1.35 $74M -
What do Analysts Say About CABA or VSTM?
Cabaletta Bio, Inc. has a consensus price target of $14.13, signalling upside risk potential of 547.94%. On the other hand Verastem, Inc. has an analysts' consensus of $16.00 which suggests that it could grow by 103.3%. Given that Cabaletta Bio, Inc. has higher upside potential than Verastem, Inc., analysts believe Cabaletta Bio, Inc. is more attractive than Verastem, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CABACabaletta Bio, Inc.7 2 0 VSTMVerastem, Inc.8 0 0 -
Is CABA or VSTM More Risky?
Cabaletta Bio, Inc. has a beta of 3.171, which suggesting that the stock is 217.108% more volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.798%.
-
Which is a Better Dividend Stock CABA or VSTM?
Cabaletta Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cabaletta Bio, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CABA or VSTM?
Cabaletta Bio, Inc. quarterly revenues are --, which are smaller than Verastem, Inc. quarterly revenues of $11.2M. Cabaletta Bio, Inc.'s net income of -$44.9M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Cabaletta Bio, Inc.'s price-to-earnings ratio is -- while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cabaletta Bio, Inc. is -- versus 36.78x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CABACabaletta Bio, Inc.-- -- -- -$44.9M VSTMVerastem, Inc.36.78x -- $11.2M -$98.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
